Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
This was the stock's third consecutive day of gains.
Analysts Set Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target at $494.04
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...
Vertex wins approval for new once-daily CF drug
Vertex Pharmaceuticals Inc. notched two FDA victories late Friday for its cystic fibrosis medicines, increasing the number of ...
Nasdaq4d
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex Pharmaceuticals (VRTX ... Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Everence Capital Management Inc.
Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Vertex Pharmaceuticals (VRTX) Receives a Buy from Bank of America Securities
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...
Yahoo Finance10d
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
Vertex Pharmaceuticals (NASDAQ ... quarter -- and a significant portion of the programs in its research and development (R&D) pipeline. Its steady work over the year delivered a large market ...